Calcitriol for Oral Mucositis Prevention in Patients With Fanconi Anemia Undergoing Hematopoietic Sct: A Double-Blind, Randomized, Placebo-Controlled Trial Publisher Pubmed



Hamidieh AA¹ ; Sherafatmand M² ; Mansouri A³ ; Hadjibabaie M^{2, 3} ; Ashouri A⁴ ; Jahangardrafsanjani Z^{2, 3} ; Gholami K^{2, 3} ; Javadi MR^{2, 3} ; Ghavamzadeh A¹ ; Radfar M^{2, 3}
Source: American Journal of Therapeutics Published:2016

Abstract

Fanconi anemia is a rare inherited aplastic anemia, which is cured only by hematopoietic stem-cell transplantation (HSCT). One of the most debilitating complications of high-dose chemotherapy regimen before HSCT is oral mucositis (OM), which occurs frequently in this population. Vitamin D has identified immunoregulatory, anti-inflammatory, and antioxidant role. This study was designed to examine the efficacy of Vitamin D in the prevention of OM in patients with Fanconi anemia undergoing allogenic HSCT. Twenty-eight patients were enrolled in the study. They received either calcitriol (0.025 mg) or placebo capsule once daily, from the first day of chemotherapy schedule for 14 consecutive days. Incidence of OM was assessed as the primary outcome. Moreover, the association of baseline Vitamin D level with OM was evaluated. In this study, calcitriol did not change OM incidence (P 5 1) and severity (P 5 0.54) significantly; however, a significant association of baseline Vitamin D level with OM complete resolution was found (P 5 0.03; hazard ratio, 1.01; 95% confidence interval, 1.00-1.01). In conclusion, we did not find considerable benefits of calcitriol in the prevention of OM. However, further studies with bigger sample size and different calcitriol supplementation schedules are needed to confirm these findings. Copyright © 2015 Wolters Kluwer Health, Inc.